Avadel Pharmaceuticals Plc Revenue Growth Rates (AVDL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Avadel Pharmaceuticals Plc  (NASDAQ: AVDL)
 

AVDL's Revenue Growth by Quarter and Year

Avadel Pharmaceuticals Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AVDL Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September 77.47
2nd Quarter June 67.76
1st Quarter March 51.93
FY 197.16

AVDLs Annual Revenue
Avadel Pharmaceuticals Plc's Revenue in the fiscal year 2024 $ 168.84 millions
Avadel Pharmaceuticals Plc's Revenue in the fiscal year 2022 $ 0.00 millions
Avadel Pharmaceuticals Plc's Revenue in the fiscal year 2021 $ 0.00 millions
Avadel Pharmaceuticals Plc's Revenue in the fiscal year 2020 $ 22.33 millions
Avadel Pharmaceuticals Plc's Revenue in the fiscal year 2019 $ 59.22 millions




AVDL Revenue third quarter 2025 Y/Y Growth Comment
Avadel Pharmaceuticals Plc reported Revenue rise of 55.34% year on year in the third quarter 2025, to $ 77.47 millions, this is lower than Avadel Pharmaceuticals Plc's recent average Revenue surge of 145.83%.

Looking into third quarter 2025 results within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Revenue growth. While Avadel Pharmaceuticals Plc' s Revenue jump of 55.34% ranks overall at the positon no. 163 in the third quarter 2025.


AVDL Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 636.09 % - -
3rd Quarter September 55.34 % 3224.67 % - -
2nd Quarter June 66.4 % - - -
1st Quarter March 94.79 % - - -
FY   - 1884.14 % - -

Financial Statements
Avadel Pharmaceuticals Plc's third quarter 2025 Revenue $ 77.47 millions AVDL's Income Statement
Avadel Pharmaceuticals Plc's third quarter 2024 Revenue $ 49.87 millions Quarterly AVDL's Income Statement


AVDL Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 3.47 % 367.33 % -
3rd Quarter September 14.33 % 22.47 % - -
2nd Quarter June 30.48 % 52.74 % - -
1st Quarter March 0.64 % 280.31 % - -
FY (Year on Year)   - 1884.14 % - -


Back to AVDL Growth rate Comparisons >> Back to AVDL Growth rate Comparisons >>


Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #44
Overall #163

Revenue Y/Y Growth Statistics
High Average Low
191.46 % 145.83 % 100.2 %
(Jun 30 2025)   (Sep 30 2025)
Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #44
Overall #163
Revenue Y/Y Growth Statistics
High Average Low
191.46 % 145.83 % 100.2 %
(Jun 30 2025)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Avadel Pharmaceuticals Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
368.85 % 29.22 % -100 %
(Sep 30 2023)  


AVDL's III. Quarter Q/Q Revenue Comment
Avadel Pharmaceuticals Plc achieved in the III. Quarter 2025 below company average Revenue rise of 14.33% quarter on quarter, to $ 77.47 millions.

Within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue quarter on quarter growth. While Avadel Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 570.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #115
Overall #570
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #115
Overall #570
Revenue Q/Q Growth Statistics
High Average Low
368.85 % 29.22 % -100 %
(Sep 30 2023)  


AVDL's III. Quarter Q/Q Revenue Comment
Avadel Pharmaceuticals Plc achieved in the III. Quarter 2025 below company average Revenue rise of 14.33% quarter on quarter, to $ 77.47 millions.

Within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue quarter on quarter growth. While Avadel Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 570.


Avadel Pharmaceuticals Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)
Cumulative Revenue 12 Months Ending $ 248.76 $ 221.17 $ 194.12 $ 168.84 $ 124.26
Y / Y Revenue Growth (TTM) 100.2 % 191.46 % - - -
Year on Year Revenue Growth Overall Ranking # 55 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 12.48 % 13.93 % 14.97 % 35.88 % 63.75 %
Seq. Revenue Growth (TTM) Overall Ranking # 177 # 0 # 46 # 106 # 146


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2025 period, Avadel Pharmaceuticals Plc's cumulative twelve months Revenue were $ 249 millions, company would post below average annual Revenue growth of 63.75% year on year, if the fiscal year would end at Sep 30 2025.
A slow-down in the Avadel Pharmaceuticals Plc's Revenue growth from the 67.76% growth in Jun 30 2025.

Among companies within the Healthcare sector 17 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 55.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 24
Healthcare Sector # 18
Overall # 55

Revenue TTM Y/Y Growth Statistics
High Average Low
191.46 %
 145.83 %
100.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 46
S&P 500 # 177
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2025 period, Avadel Pharmaceuticals Plc's cumulative twelve months Revenue were $ 249 millions, company would post below average annual Revenue growth of 100.2% year on year, if the fiscal year would end at Sep 30 2025.
A slow-down in the Avadel Pharmaceuticals Plc's Revenue growth from the 67.76% growth in Jun 30 2025.

Among companies within the Healthcare sector 17 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 55.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 24
Healthcare Sector # 18
Overall # 55

Revenue TTM Y/Y Growth Statistics
High Average Low
191.46 %
145.83 %
100.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 46
S&P 500 # 177




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AVDL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2025
Carlsmed Inc 96.16%$ 96.161 millions
Tg Therapeutics Inc 92.79%$ 92.788 millions
Bolt Biotherapeutics Inc 90.10%$ 90.096 millions
Delcath Systems Inc 88.82%$ 88.816 millions
Profound Medical Corp 86.76%$ 86.758 millions
Kaya Holdings Inc 80.27%$ 80.267 millions
Fennec Pharmaceuticals Inc 78.69%$ 78.692 millions
Vivos Therapeutics Inc 78.07%$ 78.074 millions
Insmed Inc77.99%$ 77.994 millions
Premier Air Charter Holdings Inc 75.89%$ 75.893 millions
Zymeworks Inc 72.59%$ 72.588 millions
Hologic Inc71.51%$ 71.508 millions
Legend Biotech Corporation69.99%$ 69.988 millions
Assertio Holdings inc 69.36%$ 69.357 millions
Esperion Therapeutics Inc 69.10%$ 69.099 millions
Bespoke Extracts Inc68.63%$ 68.630 millions
Xenetic Biosciences Inc 67.19%$ 67.191 millions
Geron Corporation67.05%$ 67.051 millions
Axsome Therapeutics Inc 63.22%$ 63.219 millions
Beta Bionics Inc 62.34%$ 62.341 millions
Uniqure N v 61.83%$ 61.828 millions
Evoke Pharma Inc 61.40%$ 61.405 millions
Kiniksa Pharmaceuticals International Plc61.17%$ 61.170 millions
Precision Optics Corporation Inc 59.18%$ 59.179 millions
Assembly Biosciences Inc 57.62%$ 57.619 millions
Akebia Therapeutics Inc 57.01%$ 57.011 millions
Sonoma Pharmaceuticals Inc 56.58%$ 56.580 millions
Schrodinger Inc 56.43%$ 56.427 millions
Avadel Pharmaceuticals Plc55.34%$ 55.338 millions
Rhythm Pharmaceuticals Inc 54.28%$ 54.275 millions


About Avadel Pharmaceuticals Plc Revenue Growth Rates (AVDL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Avadel Pharmaceuticals Plc (CIK 1012477).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001012477-25-000031
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Avadel Pharmaceuticals Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.